Fig. 1 · Structure

Documents & Downloads

Isoliquiritigenin

Cat. No. A10482 CAS 961-29-5

NLRP3 inflammasome inhibitor

Isoliquiritigenin is a licorice chalconoid, a type of natural phenols that is currently under experimentation phase testing for use as a cancer treatment as well as an aide for cocaine addiction.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In RAW 264.7 macrophages, isoliquiritigenin increased ARE reporter activity and nuclear Nrf2. Attenuation by compound C supports AMPK involvement, without establishing direct binding to AMPK or Nrf2. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Aldose reductase 320 nM

Cellular Effect

Cell Line Activity Value Description Reference
3T3-L1 IC50 96.4 μM Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining [PMID: 19757853]
A549 IC50 > 20 μM Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay [PMID: 19883086]
A549 IC50 52.58 μM Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay [PMID: 34186178]
A549 IC50 85 μM Cytotoxicity against human A549 cells after 72 hrs by MTT assay [PMID: 21696954]
A549 GI50 87 μM Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay [PMID: 32345458]
A549 IC50 98.9 μM Cytotoxicity against human A549 cells after 72 hrs by MTT assay [PMID: 18440233]
B16-BL6 IC50 80.5 μM Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay [PMID: 18440233]
BV-2 IC50 > 100 μM Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay [PMID: 28911817]
C2C12 IC50 26.34 μg/mL Cytotoxicity against mouse C2C12 cells assessed as reduction in cell viability by MTT assay [PMID: 33412152]
C-33-A IC50 32.83 μM Cytotoxicity against human C33A cells assessed as reduction in cell viability after 72 hrs [PMID: 31539776]
Ca-Ski IC50 39.09 μM Cytotoxicity against human CaSki cells assessed as reduction in cell viability after 72 hrs [PMID: 31539776]
CHO IC50 45.9 μM Cytotoxicity against CHO cells by MTT assay [PMID: 19572738]
HCT-116 GI50 39 μM Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay [PMID: 32345458]
HEK-293T IC50 3.42 μg/mL Inhibition of oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant activity expressed in HEK293T cells after 2 hrs by spectrofluorometry [PMID: 21123068]
HEK-293T IC50 3.48 μg/mL Inhibition of wild type H1N1 swine influenza virus neuraminidase activity expressed in HEK293T cells after 2 hrs by spectrofluorometry [PMID: 21123068]
HeLa IC50 58.1 μM Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 31539776]
HeLa IC50 58.1 μM Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs [PMID: 31539776]
HeLa IC50 82.6 μM Cytotoxicity against human HeLa cells after 72 hrs by MTT assay [PMID: 18440233]
HepG2 IC50 27.71 μM Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay [PMID: 34186178]
HT-1080 IC50 76.7 μM Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay [PMID: 18440233]

20 records · Scroll to view more

Isoliquiritigenin Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Isoliquiritigenin from 2 published references. In vitro models include murine RAW 264.7 macrophage cell line.

Isoliquiritigenin In Vitro Studies

Isolated isoliquiritigenin inhibited CYP2C8 and CYP2C9 by more than 50% at 10 µM in a human liver microsome screen. Other CYP responses varied by isoform and substrate. These single-concentration results do not establish an IC50 or a clinical drug interaction. [2]

AMPK/Nrf2 signaling in RAW 264.7 macrophages

Cell-based study · Murine RAW 264.7 macrophage cell line [1]

Isoliquiritigenin increased ARE reporter activity, nuclear Nrf2 and antioxidant-enzyme expression. Compound C attenuated AMPK phosphorylation and nuclear Nrf2, supporting pathway involvement without proving a direct molecular target.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ARE reporter activity and Nrf2 nuclear accumulationdirection Increased[1]
ISL-induced AMPK phosphorylation and nuclear Nrf2 with compound Cdirection Attenuated by compound C[1]

Literature-Reported Treatment Conditions

Treatment concentration
5, 10, 20 µM for reporter concentration series; 20 µM for time courses
Exposure duration
Reporter: 18 h concentration series or 1, 3, 6, 18 h; Nrf2 blots: 1, 3, 6 h; enzyme blots: 1, 3, 6, 18 h; AMPK blots: 0.5, 1, 3 h
Method
Cell treatment; dual-luciferase ARE reporter and immunoblotting
Co-treatment
Compound C 5 µM for 24 h followed by ISL for 3 h in Figure 2F; not part of ISL-only series.
Reported limits
Solvent and final vehicle concentration are not specified for Figure 2. Caption reports n = 5 without defining independent biological repeats.
Methods and source locations

Compound reported in the paper: Isoliquiritigenin; Compound label in the paper: ISL

Research findings for the tested material; does not validate an Adooq lot or establish clinical efficacy.

S2-1–S2-4, S2-15–S2-17; S3-2; Figure 2A–F

ARE reporter activity and Nrf2 nuclear accumulation: Dual-luciferase reporter; Nrf2 blots with β-actin and Lamin B controls; mean ± SEM, n = 5 as captioned. — Figure 2A–D; S3-2

ISL-induced AMPK phosphorylation and nuclear Nrf2 with compound C: Immunoblots; control, ISL, compound C, combination; mean ± SEM, n = 5 as captioned. Pharmacological inhibition does not establish inhibitor specificity. — Figure 2E–F; S3-2

CYP inhibition by isolated isoliquiritigenin in human liver microsomes

Biochemical assay · Pooled mixed-gender human liver microsomes from 200 donors; probe-substrate cocktail [2]

At 10 µM, isolated isoliquiritigenin inhibited CYP2C8 and CYP2C9. Figure 3 shows little inhibition of CYP2A6 and CYP2D6 and a substrate-dependent CYP3A4 response. This is a single-concentration enzyme screen, not an isoliquiritigenin IC50 or a demonstrated clinical interaction.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CYP2C8 and CYP2C9 activity relative to no-inhibitor controlinhibition >50% at 10 µM[2]
Other CYP isoforms in the same screenqualitative profile Little inhibition of CYP2A6/CYP2D6; greater CYP3A4 inhibition with testosterone than midazolam[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
10 min incubation
Method
Probe-substrate turnover quantified by UHPLC-MS/MS
Vehicle
Methanol solvent control (0.5 µL)
Co-treatment
No compound combination: constituents tested individually.
Reported limits
Figure 3 experiments performed in duplicate; replicate type and error-bar definition not specified in the caption. Isoliquiritigenin IC50 was not determined in this screen.
Methods and source locations

Compound reported in the paper: Isoliquiritigenin; Compound label in the paper: isoliquiritigenin

Research findings for the tested material; does not validate an Adooq lot or establish clinical efficacy.

Sections 2.1, 2.3–2.4; section 3 constituent-screen paragraph; Figures 1 and 3

CYP2C8 and CYP2C9 activity relative to no-inhibitor control: UHPLC-MS/MS cocktail screen; section 3 explicitly states >50% inhibition for active compounds and identifies isoliquiritigenin CYP2C8/2C9 effects; Figure 3 confirms. Duplicate experiments. — Section 3 constituent-screen paragraph; Figure 3 isoliquiritigenin panel; sections 2.3–2.4

Other CYP isoforms in the same screen: Viewed Figure 3; qualitative only, no percentages estimated from bars. — Figure 3 isoliquiritigenin panel and caption

Isoliquiritigenin In Vivo Studies

In a mouse acute lung injury model, a single 30 mg/kg intraperitoneal dose of isoliquiritigenin given before challenge reduced lung injury in wild-type mice. Protection was substantially weakened in Nrf2-deficient mice. NLRP3, ASC and caspase-1-p10 increased in the knockout comparison even though IL-1β and NF-κB-associated readouts decreased, limiting any claim of uniform inflammasome suppression. [1]

Nrf2 genotype modifies the pulmonary response to isoliquiritigenin

Animal study · Wild-type and Nrf2−/− C57BL/6 mice in an LPS-induced acute lung injury model [1]

Pretreatment reduced lung injury and NLRP3/ASC/caspase-1-p10 in wild-type mice. The injury-score benefit was substantially weakened in Nrf2−/− mice, where NLRP3, ASC and caspase-1-p10 increased relative to LPS alone. NF-κB-associated readouts and pro-/mature IL-1β still decreased in the knockout comparison; responses therefore depend on both genotype and endpoint.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Histological lung injury scoredirection Reduced in wild-type; benefit substantially weakened in Nrf2−/− mice[1]
Lung NLRP3, ASC and caspase-1-p10direction Decreased in wild-type; increased in Nrf2−/− mice versus genotype-matched LPS alone[1]
Pro-/mature IL-1β and NF-κB-associated readouts in Nrf2−/− micedirection Decreased despite increased NLRP3/ASC/caspase-1-p10[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single dose
Treatment course
1 h before LPS; lung collection 12 h after LPS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Wild-type
30 mg/kg
Within-genotype untreated, ISL-only and LPS-only groupsLower lung injury score and NLRP3/ASC/caspase-1-p10 than challenge alone.[1]
Nrf2−/−
30 mg/kg
Within-genotype untreated, ISL-only and LPS-only groupsWeak injury-score benefit; NLRP3/ASC/caspase-1-p10 increased, while IL-1β and NF-κB-related endpoints decreased versus challenge alone.[1]
Wild-type
Model: Wild-type C57BL/6 mice
Reported limits: Vehicle, sex and age not specified in relevant methods.
Nrf2−/−
Model: Nrf2−/− C57BL/6 mice
Reported limits: Vehicle, sex and age not specified in relevant methods.
Methods and source locations

Compound reported in the paper: Isoliquiritigenin; Compound label in the paper: ISL

Research findings for the tested material; does not validate an Adooq lot or establish clinical efficacy.

S2-1, S2-5–S2-6, S2-8, S2-15–S2-17; S3-9; Figures 9–10

Histological lung injury score: Blinded H&E injury scoring; Figure 9B n = 5; no exact bar heights inferred. — Figure 9A–B; S3-9; S2-8

Lung NLRP3, ASC and caspase-1-p10: Immunoblots with β-actin control; mean ± SEM, n = 5; Figure 10 uses $$ for P < 0.01 upregulation versus LPS. — Figure 10 upper panels; S3-9

Pro-/mature IL-1β and NF-κB-associated readouts in Nrf2−/− mice: Figure 10 viewed: IL-1β bands/densitometry, p-IκBα, nuclear p65; β-actin/Lamin B controls; mean ± SEM, n = 5. — Figure 10; S3-9

Wild-type · S2-5–S2-6; Figures 9–10; S3-9

Nrf2−/− · S2-5–S2-6; Figures 9–10; S3-9

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 961-29-5
Applications NLRP3 inflammasome inhibitor
Formula C15H12O4
Molecular Weight 256.3
SMILES
C1=CC(=CC=C1/C=C/C(=O)C2=C(C=C(C=C2)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 10 mg/mL (39.02 mM)
Water Insoluble
Ethanol 23 mg/mL (89.75 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Isoliquiritigenin Research References

  1. [1] Qinmei Liu, Hongming Lv, Zhongmei Wen, et al. Isoliquiritigenin Activates Nuclear Factor Erythroid-2 Related Factor 2 to Suppress the NOD-Like Receptor Protein 3 Inflammasome and Inhibits the NF-κB Pathway in Macrophages and in Acute Lung Injury Frontiers in Immunology (2017). PMID: 29163554 DOI: 10.3389/fimmu.2017.01518 Source material
  2. [2] Guannan Li, Charlotte Simmler, Luying Chen, et al. Cytochrome P450 inhibition by three licorice species and fourteen licorice constituents. European Journal of Pharmaceutical Sciences (2017). PMID: 28774812 DOI: 10.1016/j.ejps.2017.07.034 Source material

Added to your cart

View Cart Checkout
Loading...